Engineered immune cells take on lupus and scleroderma in new trial
NCT ID NCT07315087
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage study is testing a new type of cell therapy (called QT-019C) in 12 adults with severe autoimmune diseases like lupus and scleroderma that have not responded to standard treatments. The therapy uses specially engineered immune cells from a healthy donor to target and potentially reset the faulty immune system. The main goal is to check safety, but researchers will also look for signs that the treatment can control the disease.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ANCA ASSOCIATED VASCULITIS (AAV) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Institute of Hematology & Blood Diseases Hospital
RECRUITINGTianjin, China, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a targeted antibody tame kidney inflammation without heavy steroids?
- Can a simple blood test unlock the secrets of brain autoimmune diseases?
- Engineered immune cells take aim at Hard-to-Treat muscle disease
- Engineered immune cells take aim at childhood autoimmune diseases
- New study aims to unlock secrets of rare muscle disease
- HIV drug repurposed to fight muscle inflammation